纳米组装介导的exendin-4衍生物可降低脏保留率
Zhengwei Zhou1,2, Shuai Wang1,2, Tianling Feng1,2
1Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Changle Road 68, Nanjing 210006, P. R. China.
ACS omega
|May 6, 2024
概括
新的Exendin-4纳米设备有效地向胰岛素瘤,减少脏积累. 这些新型纳米粒子显示出显著的瘤抑制,在癌症治疗和诊断方面提供了有前途的进步.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 68Ga-Exendin-4显示了胰岛素瘤的诊断潜力,但患有高保留.
- 纳米粒子策略在准和有效载荷交付方面具有优势.
- 开发新的Exendin-4衍生物对于改善治疗结果至关重要.
研究的目的:
- 开发和评估用于胰岛素瘤的基于Exendin-4衍生物的放射性核素纳米器件.
- 评估这些纳米组件的准效率,生物分布和治疗疗效.
- 为了克服传统的Ga-Exendin-4结合物的局限性.
主要方法:
- 合成了三角质块重组蛋白Exendin-4衍生物.
- 通过反向过渡周期 (ITC) 实现了净化.
- 在生理条件下诱导了纳米设备的自我组装.
主要成果:
- 同质的球形纳米粒子是由Exendin-4衍生物形成的.
- 纳米组件对胰岛素瘤细胞和瘤组织中的体内沉积具有很高的亲和力.
- 与传统结合剂相比,观察到保留率减少了五倍.
- 取得了显著的瘤抑制效果.
结论:
- 埃克森丁-4衍生纳米组件代表了胰岛素瘤诊断和治疗的有前途平台.
- 纳米粒子配方显著改善了向,并减少了非向积累,特别是在脏中.
- 这种方法为治疗胰岛素瘤提供了增强的疗效和潜在的安全性.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.3K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:28Renal Drug Excretion: Tubular Secretion
176
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
176